|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
|
PL2068909T3
(pl)
|
2007-03-30 |
2012-09-28 |
Ambrx Inc |
Modyfikowane polipeptydy fgf-21 i ich zastosowanie
|
|
ES2692495T3
(es)
|
2009-01-23 |
2018-12-03 |
Novo Nordisk A/S |
Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
|
|
EP2359843A1
(en)
*
|
2010-01-21 |
2011-08-24 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
CN103124562A
(zh)
*
|
2010-06-08 |
2013-05-29 |
诺沃—诺迪斯克有限公司 |
Fgf21的类似物和衍生物
|
|
JP2013533227A
(ja)
*
|
2010-06-08 |
2013-08-22 |
ノヴォ ノルディスク アー／エス |
Ｆｇｆ２１類似体および誘導体
|
|
PL2726511T3
(pl)
|
2011-07-01 |
2019-12-31 |
Ngm Biopharmaceuticals, Inc. |
Kompozycje, zastosowania i sposoby leczenia zaburzeń oraz chorób metabolicznych
|
|
EP2548570A1
(en)
*
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
|
LT2814844T
(lt)
|
2012-02-15 |
2017-10-25 |
Novo Nordisk A/S |
Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
|
|
LT2814842T
(lt)
|
2012-02-15 |
2018-11-12 |
Novo Nordisk A/S |
Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
|
|
TW201420606A
(zh)
*
|
2012-08-22 |
2014-06-01 |
Lilly Co Eli |
同源二聚體蛋白
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
EP3798228A1
(en)
|
2012-11-28 |
2021-03-31 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
SG10201705097PA
(en)
|
2012-12-21 |
2017-07-28 |
Sanofi Sa |
Functionalized exendin-4 derivatives
|
|
SG11201504815QA
(en)
|
2012-12-27 |
2015-07-30 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
EP3010546B1
(en)
|
2013-06-20 |
2017-08-09 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
NZ718962A
(en)
|
2013-10-28 |
2019-12-20 |
Ngm Biopharmaceuticals Inc |
Cancer models and associated methods
|
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
WO2015086729A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
AU2015209131B2
(en)
|
2014-01-24 |
2020-06-25 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
EP3155005A4
(en)
|
2014-06-16 |
2018-07-11 |
NGM Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN106536559B
(zh)
|
2014-07-17 |
2021-04-27 |
诺和诺德股份有限公司 |
定点诱变trem-1抗体以降低黏度
|
|
CN114129709A
(zh)
|
2014-10-23 |
2022-03-04 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
CN107108710B
(zh)
|
2014-10-24 |
2022-02-15 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP6730278B2
(ja)
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
US10392428B2
(en)
|
2014-12-17 |
2019-08-27 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
HUE044783T2
(hu)
|
2014-12-23 |
2019-11-28 |
Novo Nordisk As |
FGF21 származékok és alkalmazásaik
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
CA2994279A1
(en)
|
2015-08-04 |
2017-02-09 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
KR102670157B1
(ko)
*
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
|
CA3003616C
(en)
|
2015-11-09 |
2020-07-28 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
EP3463427A4
(en)
*
|
2016-05-25 |
2020-03-11 |
Board of Regents, The University of Texas System |
METHOD AND COMPOSITIONS FOR TREATING SECRETORIC DISEASES
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
CN107759694B
(zh)
|
2016-08-19 |
2023-01-13 |
安源医药科技（上海）有限公司 |
双特异性抗体及其制备方法与用途
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技（上海）有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
US11123438B2
(en)
|
2016-08-19 |
2021-09-21 |
Ampsource Biopharma Shanghai Inc. |
Linker peptide for constructing fusion protein
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
WO2018053201A1
(en)
|
2016-09-14 |
2018-03-22 |
Duke University |
Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs
|
|
JP2020500150A
(ja)
|
2016-09-23 |
2020-01-09 |
デューク ユニバーシティ |
下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
|
|
CN110121355B
(zh)
|
2016-11-10 |
2023-09-12 |
株式会社柳韩洋行 |
用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
|
|
EP3552022B1
(en)
*
|
2016-11-25 |
2021-06-09 |
Implexion AB |
Metabolic disorders
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
CN108570109B
(zh)
|
2017-03-14 |
2022-04-26 |
广东东阳光药业有限公司 |
包含免疫球蛋白Fc部分的双靶点融合蛋白
|
|
CN108619490A
(zh)
*
|
2017-03-22 |
2018-10-09 |
天士力医药集团股份有限公司 |
一种长效化突变的人源成纤维生长因子的新用途
|
|
AU2018256256B2
(en)
|
2017-04-21 |
2023-02-23 |
Yuhan Corporation |
Method for producing dual function proteins and its derivatives
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
US11680083B2
(en)
|
2017-06-30 |
2023-06-20 |
Duke University |
Order and disorder as a design principle for stimuli-responsive biopolymer networks
|
|
CN109836504B
(zh)
*
|
2017-11-24 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
|
WO2019119673A1
(zh)
*
|
2017-12-19 |
2019-06-27 |
北京吉源生物科技有限公司 |
一种双基因修饰的干细胞及其用途
|
|
CN109942696A
(zh)
*
|
2017-12-21 |
2019-06-28 |
中国药科大学 |
长效化胰高血糖素样肽－1（glp－1）类似物及其应用
|
|
CN110028587B
(zh)
*
|
2018-01-11 |
2021-10-08 |
安源医药科技（上海）有限公司 |
用于调节血糖和脂质的增效型双功能蛋白
|
|
WO2019147954A1
(en)
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
AU2019218147B2
(en)
|
2018-02-08 |
2023-06-08 |
Sunshine Lake Pharma Co., Ltd. |
FGF21 variant, fusion protein and application thereof
|
|
TWI790370B
(zh)
|
2018-04-02 |
2023-01-21 |
美商必治妥美雅史谷比公司 |
抗trem-1抗體及其用途
|
|
US12257308B2
(en)
|
2018-04-30 |
2025-03-25 |
Duke University |
Stimuli-responsive PEG-like polymer-based drug delivery platform
|
|
US11649275B2
(en)
|
2018-08-02 |
2023-05-16 |
Duke University |
Dual agonist fusion proteins
|
|
CA3136163A1
(en)
*
|
2019-04-11 |
2020-10-15 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Multi-receptor agonist and medical use thereof
|
|
CN111944055B
(zh)
|
2019-05-16 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
CN112279920B
(zh)
*
|
2019-07-25 |
2024-01-16 |
安源医药科技（上海）有限公司 |
FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途
|
|
CN115322794B
(zh)
*
|
2020-01-11 |
2025-09-19 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
WO2024165571A2
(en)
|
2023-02-06 |
2024-08-15 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2024199734A2
(en)
|
2023-03-30 |
2024-10-03 |
Novo Nordisk A/S |
Fusion compounds and uses thereof
|
|
WO2025125576A2
(en)
|
2023-12-15 |
2025-06-19 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
WO2025133348A1
(en)
|
2023-12-22 |
2025-06-26 |
E-Therapeutics Plc |
Inhibitors of expression and/or function
|
|
EP4686757A1
(en)
|
2024-07-31 |
2026-02-04 |
e-therapeutics PLC |
Inhibitors of expression and/or function
|
|
WO2025196502A1
(en)
|
2024-03-20 |
2025-09-25 |
North Carolina Agricultural & Technical State University |
Choline kinase inhibitors as a therapeutic treatment for obesity
|